SCHEMBL753194

SCHEMBL753194

CCOC(=O)c1ccc(N)cc1Cl

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOA P21397 2/20 0.68
CHRM2 P08172 1/20 0.68
CHRM3 P20309 1/20 0.68
HTR2C P28335 1/20 0.68
CHRNA4 P43681 1/20 0.68
HTR3A P46098 1/20 0.68
KCNH2 Q12809 1/20 0.68
HRH3 Q9Y5N1 1/20 0.68
LMNA P02545 2/20 0.54
CYP1A2 P05177 1/20 0.54
CYP3A4 P08684 1/20 0.54
ALDH1A1 P00352 3/20 0.51
HSD17B10 Q99714 3/20 0.51
GAA P10253 3/20 0.51
ALOX15 P16050 3/20 0.51
KMT2A Q03164 2/20 0.51
MAPT P10636 2/20 0.51
RAB9A P51151 2/20 0.51
SMN1; SMN2 Q16637 2/20 0.51
CYP4F2 P78329 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL27783041 0.98 MAOA (0.66) MAOACHRM2CHRM3HTR2CCHRNA4
SCHEMBL7483683 0.94 MAOA (0.61) MAOACHRM2CHRM3HTR2CCHRNA4
SCHEMBL194508 0.87 CYP4F2 (0.63) MAOACHRM2CHRM3HTR2CCHRNA4
SCHEMBL2888716 0.84 TSHR (0.60) MAOACHRM2CHRM3HTR2CCHRNA4
SCHEMBL522136 0.83 KMT2A (0.59) CYP1A2ALDH1A1ALOX15KMT2AMAPT
SCHEMBL9827284 0.83 BAZ2B (0.58) MAOACHRM2CHRM3HTR2CCHRNA4
SCHEMBL754826 0.83 LMNA (0.62) MAOACHRM2CHRM3HTR2CCHRNA4
SCHEMBL29375324 0.83 ALDH1A1 (0.64) MAOACHRM2CHRM3HTR2CCHRNA4
SCHEMBL2132644 0.83 ALDH1A1 (0.64) MAOACHRM2CHRM3HTR2CCHRNA4
SCHEMBL6705158 0.83 CHRM2 (0.59) MAOACHRM2CHRM3HTR2CCHRNA4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240199572-A1 COMPOUNDS, COMPOSITIONS, AND METHODS FOR TREATING TYPE 2 DIABETES AND DEMENTIA NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2024-06-20 US disclosed
EP-4308554-A1 COMPOUNDS, COMPOSITIONS, AND METHODS FOR TREATING TYPE 2 DIABETES AND DEMENTIA The Board of Trustees of the University of Illinois (US) 2024-01-24 EP disclosed
WO-2022197658-A1 COMPOUNDS, COMPOSITIONS, AND METHODS FOR TREATING TYPE 2 DIABETES AND DEMENTIA THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) 2022-09-22 WO disclosed
CN-103502216-B As pesticide and acaricidal indole carboxamides and benzimidazole-carboxamide BAYER INTELLECTUAL PROPERTY GMBH (DE) 2016-05-04 CN disclosed
CN-102741222-B Haloalkyl-substituted amides as insecticides and acaricides BAYER INTELLECTUAL PROPERTY GMBH (DE) 2015-12-02 CN disclosed
US-9107411-B2 Indolecarboxamides and benzimidazolecarboxamides as insecticides and acaricides BAYER INTELLECTUAL PROPERTY GMBH (DE) 2015-08-18 US disclosed
EP-2683688-B1 INDOLECARBOXAMIDES AND BENZIMIDAZOLECARBOXAMIDES AS INSECTICIDES AND ACARICIDES BAYER IP GMBH (DE) 2015-05-06 EP disclosed
US-8889878-B2 Haloalky-substituted amides as insecticides and acaricides BAYER CROPSCIENCE AG (DE) 2014-11-18 US disclosed
US-8889878-B2 Haloalky-substituted amides as insecticides and acaricides BAYER CROPSCIENCE AG (DE) 2014-11-18 US disclosed
US-8889878-B2 Haloalky-substituted amides as insecticides and acaricides BAYER CROPSCIENCE AG (DE) 2014-11-18 US disclosed
EP-0800524-A1 6- TRIAZOLYL 3-(TRIFLUOROMETHYL)PHENYL]METHYL]-2-QUINOLINONES AND -QUINOLINETHIONES JANSSEN PHARMACEUTICA N.V. (BE) 1997-10-15 EP disclosed
US-5675024-A RETINOID RECEPTOR AGONISTS ALLERGAN (US) 1997-10-07 US disclosed
WO-1997019052-A1 ARYL OR HETEROARYL AMIDES OF TETRAHYDRONAPHTHALENE, CHROMAN, THIOCHROMAN AND 1,2,3,4-TETRAHYDROQUINOLINE CARBOXYLIC ACIDS HAVING RETINOID-LIKE BIOLOGICAL ACTIVITY ALLERGAN (US) 1997-05-29 WO disclosed
WO-1996020200-A1 6-[TRIAZOLYL[3-(TRIFLUOROMETHYL)PHENYL]METHYL]-2-QUINOLINONES AND -QUINOLINETHIONES JANSSEN PHARMACEUTICA N.V. (BE) 1996-07-04 WO disclosed
US-5347052-A Preparation of 3,5-diaminobenzotrifluoride OCCIDENTAL CHEMICAL CORPORATION (US) 1994-09-13 US disclosed
US-5144076-A Preparation of 3,5-diamino benzotrifluoride OCCIDENTAL CHEMICAL CORPORATION (US) 1992-09-01 US disclosed
EP-0484767-A1 Preparation of 3,5-diamino benzotrifluoride OCCIDENTAL CHEMICAL CORPORATION (US) 1992-05-13 EP disclosed
EP-0106060-B1 IMIDAZOLE DERIVATIVES AND SALTS THEREOF, THEIR SYNTHESIS, AND PHARMACEUTICAL FORMULATIONS THE WELLCOME FOUNDATION LIMITED (GB) 1988-09-28 EP disclosed
US-4562199-A ANTICOAGULANTS WELLCOME FOUNDATION LIMITED, A CORP OF ENGLAND (GB) 1985-12-31 US disclosed
EP-0106060-A2 Imidazole derivatives and salts thereof, their synthesis, and pharmaceutical formulations THE WELLCOME FOUNDATION LIMITED (GB) 1984-04-25 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240199572-A1 COMPOUNDS, COMPOSITIONS, AND METHODS FOR TREATING TYPE 2 DIABETES AND DEMENTIA SREBF2, SREBF1, SLC2A2 MAOA 2046/4885CHRM2 663/4885CHRM3 1120/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.